Pfizer Inc (PFE) Stock Analysis and Metrics

Pfizer

NYSE: PFE

$25.05 ▼ -0.09 (-0.36%)

At close: Jul 17, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap136.01 Bn

P/E11,334.57

P/S5.56

Div. Yield0.07

ROIC (Qtr)0.00

Total Debt (Qtr)64.46 Bn

Revenue Growth (1y) (Qtr)10.70

Add ratio to table…

About

Pfizer Inc. is a research-based global biopharmaceutical company focused on the discovery, development, manufacture, marketing, sale, and distribution of biopharmaceutical products worldwide. The company applies science and global resources to deliver therapies that extend and significantly improve lives by addressing wellness, prevention, treatments, and cures for some of the most feared diseases. Pfizer collaborates with healthcare providers, governments, and local communities to expand access to reliable and affordable healthcare across developed and emerging markets.

Pfizer generates revenue primarily through the manufacture and sale of its biopharmaceutical products, including medicines and vaccines. The company believes its products provide value by improving disease treatment, enhancing health and wellness, increasing productivity, and reducing healthcare costs such as emergency room visits and hospitalizations. Pfizer seeks to maximize patient access and evaluates pricing and contracting arrangements with payors to minimize adverse revenue impacts within legal and pricing frameworks.

The company operates through the following segments: Biopharma, PC1, and Pfizer Ignite.

• Biopharma: This segment is engaged in the discovery, development, manufacture, marketing, sale, and distribution of biopharmaceutical products worldwide. It includes the commercialization of Pfizer’s entire product portfolio through divisions such as Pfizer U. S. Commercial, Pfizer International Commercial, and Global Hospital and Biosimilars. Key products in this segment include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, Paxlovid, Xeljanz, Enbrel (outside the U. S. and Canada), Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Zavicefta (outside the U. S. and Canada), Octagam, Panzyga, Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna.

• PC1: This segment operates as Pfizer’s contract development and manufacturing organization and is a leading supplier of specialty active pharmaceutical ingredients. PC1 provides development and manufacturing services to support both internal and external clients, focusing on complex molecule synthesis and formulation. The segment leverages Pfizer’s technical expertise in chemical development and process optimization to deliver high-quality active pharmaceutical ingredients for various therapeutic areas.

• Pfizer Ignite: This segment provided strategic guidance and end-to-end research and development services to select innovative biotech companies aligned with Pfizer’s R&D focus areas. In 2025, Pfizer made the decision to discontinue Pfizer Ignite and is winding down the business while collaborating closely with Ignite partners to ensure continuity and successful transition of work. The segment previously supported early-stage innovation through mentorship, funding, and access to Pfizer’s scientific and commercial resources.

Pfizer holds a leading position in the global biopharmaceutical industry, competing with major companies such as Merck & Co., Johnson & Johnson, Roche, Novartis, and AstraZeneca. The company’s competitive advantages stem from its extensive research and development pipeline, strong portfolio of patent-protected and biosimilar products, global commercial reach, and strategic focus on high-growth therapeutic areas including oncology, inflammation and immunology, rare diseases, and vaccines. Pfizer’s scale in manufacturing, combined with its investments in AI across R&D, manufacturing, commercial, and patient engagement, enhances its ability to innovate and improve productivity.

Pfizer serves a diverse customer base that includes hospitals, patients, healthcare providers, governments, and payors worldwide. The company works directly with physicians and medical professionals to prescribe and administer its medicines and vaccines. Pfizer collaborates with governmental and international health organizations to support vaccination programs and public health initiatives. Additionally, the company engages with insurance providers and payors to manage reimbursement and access to its therapies across different healthcare systems.

Investment Thesis

▲ Bull case

Pfizer's recent legal victories, including the Vyndamax patent settlement extending U.S. exclusivity to June 2031 and the favorable Belgian court ruling on Comirnaty contracts, are underappreciated by the market as catalysts for durable long-term value. The Vyndamax settlement alone transforms the growth profile post-2028 by delaying a potential $14–15 billion LOE cliff to mid-2031, providing an additional 2.5 years of stable, high-margin revenue from a product generating approximately $1.6 billion in Q1 2026 sales. This extension, combined with the Belgian court decision requiring Poland and Romania to accept €1.9 billion ($2.22 billion) worth of Comirnaty vaccines, creates a clearer line of sight to the high single-digit 5-year revenue CAGR starting in 2029 that management highlighted. Crucially, these legal developments enhance cash flow visibility and reduce near-term capital allocation pressure, allowing Pfizer to maintain its dividend while strategically deploying its $7 billion BD capacity toward higher-return opportunities like the Innovent ADC partnership, rather than being forced into defensive maneuvers to offset imminent patent cliffs. The market is underestimating how these specific legal wins de-risk the 2029–2033 growth trajectory and provide a foundation for sustainable EPS growth beyond what is currently modeled.
The strategic collaboration with Innovent Biologics represents a hidden catalyst that management did not heavily promote during the earnings call but holds significant asymmetric upside for Pfizer's oncology pipeline. Under the agreement, Innovent receives a $650 million upfront payment and is eligible for up to $9.85 billion in milestone payments, with Pfizer leading global development after Innovent completes Phase 1. This structure allows Pfizer to access 12 early-stage ADC and multi-specific antibody programs—eight from Innovent's discovery engine and four Pfizer-proposed—with shared costs for select programs and profit-sharing in the U.S. and Europe for co-developed, co-commercialized assets. Importantly, Innovent retains rights in Greater China, which mitigates Pfizer's upfront risk while still providing exposure to a lucrative market through royalties. The deal's total potential value of up to $10.5 billion, including double-digit royalties, significantly bolsters Pfizer's pipeline in high-growth areas like ADCs without requiring large, dilutive M&A. Given Pfizer's stated focus on AI transformation and internal R&D productivity, this partnership leverages external innovation efficiently, accelerating breakthroughs that could redefine standards of care in hematologic malignancies and solid tumors—areas where Pfizer already has strong commercial infrastructure and scientific expertise, yet the market is not fully pricing in the probability of multiple blockbuster outcomes from this collaboration over the next 5–7 years.
Pfizer's obesity franchise, anchored by the Metsera acquisition and the ecnoglutide launch in China, is positioned to capture substantial growth in an underserved global market that the market is overlooking due to near-term execution focus. The company highlighted that chronic weight management affects 15% of the Chinese population—a massive addressable market given China's size—and ecnoglutide demonstrated 15.1% weight loss at 48 weeks in placebo-controlled trials, in line with best-in-class GLP-1s. Critically, Pfizer is not entering the market late, as Lilly's similar asset launched only at the beginning of 2025, and Pfizer is leveraging its strong primary care capabilities in China, where it is already a leader. Beyond China, Pfizer sees significant opportunity in emerging markets like Brazil, Mexico, and Saudi Arabia, where obesity prevalence is high and reimbursement pathways are less complex than in Europe or Japan, allowing for faster cash-market uptake. The Metsera asset provides not only a pipeline of ultra-long-acting peptides targeting 2028 first approval but also a differentiated monthly maintenance dosing schedule that could improve adherence and tolerability. With nearly 60% of physicians likely to write obesity prescriptions already touched by Pfizer's field force, the company has unique capabilities to activate patients and consumers, yet the market remains fixated on near-term LOE headwinds and underestimates the scalable, global revenue potential from this franchise as it scales through 2028 and beyond.
The advancement of Pfizer's next-generation pneumococcal vaccine platform, particularly the 35-valent adult candidate (35vPnC), is an underappreciated long-term catalyst that leverages existing commercial infrastructure and addresses a critical unmet need in adult immunization. Building on the strong Phase 2 immunogenicity data for the 25-valent pediatric candidate (25vPnC)—which showed up to 15-fold higher antibody levels against serotype 3 compared to Prevnar 20—Pfizer has decided to advance directly to a fifth-generation adult vaccine covering 35 serotypes, with clinical development expected to begin by end of 2026. This move is strategic because serotype 3 remains a key driver of residual pneumococcal disease, and the vaccine's proprietary next-generation technology aims to improve immunogenicity for this critical strain. With Prevnar 20 already generating substantial revenue and Pfizer's leadership in pneumococcal vaccines supported by large pediatric and at-risk adult populations (50+ years), the 35vPnC candidate has the potential to maintain and extend market leadership in a durable, cash-generative franchise. Unlike oncology assets that face prolonged reimbursement negotiations, vaccines benefit from established public health procurement channels, and the adult market represents a significant growth avenue as aging populations increase demand for preventive care. The market is not fully crediting Pfizer's ability to sustain vaccine leadership through innovation, instead viewing it as a mature franchise vulnerable to competition, when in reality the 35vPnC platform could drive meaningful top-line growth well into the 2030s.

Pfizer's recent legal victories, including the Vyndamax patent settlement extending U.S. exclusivity to June 2031 and the favorable Belgian court ruling on Comirnaty contracts, are underappreciated by the market as catalysts for durable long-term value. The Vyndamax settlement alone transforms the growth profile post-2028 by delaying a potential $14–15 billion LOE cliff to mid-2031, providing an additional 2.5 years of stable, high-margin revenue from a product generating approximately $1.6 billion in Q1 2026 sales. This extension, combined with the Belgian court decision requiring Poland and Romania to accept €1.9 billion ($2.22 billion) worth of Comirnaty vaccines, creates a clearer line of sight to the high single-digit 5-year revenue CAGR starting in 2029 that management highlighted. Crucially, these legal developments enhance cash flow visibility and reduce near-term capital allocation pressure, allowing Pfizer to maintain its dividend while strategically deploying its $7 billion BD capacity toward higher-return opportunities like the Innovent ADC partnership, rather than being forced into defensive maneuvers to offset imminent patent cliffs. The market is underestimating how these specific legal wins de-risk the 2029–2033 growth trajectory and provide a foundation for sustainable EPS growth beyond what is currently modeled.
The strategic collaboration with Innovent Biologics represents a hidden catalyst that management did not heavily promote during the earnings call but holds significant asymmetric upside for Pfizer's oncology pipeline. Under the agreement, Innovent receives a $650 million upfront payment and is eligible for up to $9.85 billion in milestone payments, with Pfizer leading global development after Innovent completes Phase 1. This structure allows Pfizer to access 12 early-stage ADC and multi-specific antibody programs—eight from Innovent's discovery engine and four Pfizer-proposed—with shared costs for select programs and profit-sharing in the U.S. and Europe for co-developed, co-commercialized assets. Importantly, Innovent retains rights in Greater China, which mitigates Pfizer's upfront risk while still providing exposure to a lucrative market through royalties. The deal's total potential value of up to $10.5 billion, including double-digit royalties, significantly bolsters Pfizer's pipeline in high-growth areas like ADCs without requiring large, dilutive M&A. Given Pfizer's stated focus on AI transformation and internal R&D productivity, this partnership leverages external innovation efficiently, accelerating breakthroughs that could redefine standards of care in hematologic malignancies and solid tumors—areas where Pfizer already has strong commercial infrastructure and scientific expertise, yet the market is not fully pricing in the probability of multiple blockbuster outcomes from this collaboration over the next 5–7 years.
Pfizer's obesity franchise, anchored by the Metsera acquisition and the ecnoglutide launch in China, is positioned to capture substantial growth in an underserved global market that the market is overlooking due to near-term execution focus. The company highlighted that chronic weight management affects 15% of the Chinese population—a massive addressable market given China's size—and ecnoglutide demonstrated 15.1% weight loss at 48 weeks in placebo-controlled trials, in line with best-in-class GLP-1s. Critically, Pfizer is not entering the market late, as Lilly's similar asset launched only at the beginning of 2025, and Pfizer is leveraging its strong primary care capabilities in China, where it is already a leader. Beyond China, Pfizer sees significant opportunity in emerging markets like Brazil, Mexico, and Saudi Arabia, where obesity prevalence is high and reimbursement pathways are less complex than in Europe or Japan, allowing for faster cash-market uptake. The Metsera asset provides not only a pipeline of ultra-long-acting peptides targeting 2028 first approval but also a differentiated monthly maintenance dosing schedule that could improve adherence and tolerability. With nearly 60% of physicians likely to write obesity prescriptions already touched by Pfizer's field force, the company has unique capabilities to activate patients and consumers, yet the market remains fixated on near-term LOE headwinds and underestimates the scalable, global revenue potential from this franchise as it scales through 2028 and beyond.
The advancement of Pfizer's next-generation pneumococcal vaccine platform, particularly the 35-valent adult candidate (35vPnC), is an underappreciated long-term catalyst that leverages existing commercial infrastructure and addresses a critical unmet need in adult immunization. Building on the strong Phase 2 immunogenicity data for the 25-valent pediatric candidate (25vPnC)—which showed up to 15-fold higher antibody levels against serotype 3 compared to Prevnar 20—Pfizer has decided to advance directly to a fifth-generation adult vaccine covering 35 serotypes, with clinical development expected to begin by end of 2026. This move is strategic because serotype 3 remains a key driver of residual pneumococcal disease, and the vaccine's proprietary next-generation technology aims to improve immunogenicity for this critical strain. With Prevnar 20 already generating substantial revenue and Pfizer's leadership in pneumococcal vaccines supported by large pediatric and at-risk adult populations (50+ years), the 35vPnC candidate has the potential to maintain and extend market leadership in a durable, cash-generative franchise. Unlike oncology assets that face prolonged reimbursement negotiations, vaccines benefit from established public health procurement channels, and the adult market represents a significant growth avenue as aging populations increase demand for preventive care. The market is not fully crediting Pfizer's ability to sustain vaccine leadership through innovation, instead viewing it as a mature franchise vulnerable to competition, when in reality the 35vPnC platform could drive meaningful top-line growth well into the 2030s.

▼ Bear case

Pfizer's reliance on its pipeline to offset looming patent expirations faces significant execution risk, particularly in oncology and obesity, where clinical success is far from guaranteed despite management's optimistic framing. The company is targeting approximately 20 pivotal study starts in 2026, including high-stakes readouts for programs like atirmociclib (CDK4 inhibitor), SV (integrin B6C), and Mevro (EZH2 inhibitor), yet the earnings call revealed evasiveness when questioned about specific timelines—for instance, Chris Boshoff noted that amylin mono data from the obesity program would not be shared at ADA and would only come in the second half of the year, signaling potential delays. While management cites statistical confidence in a "large number of pipeline assets risk adjusted," the reality is that late-stage oncology programs carry high failure rates; for example, the TALAPRO-3 study of Talzenna plus Xtandi in mCSPC, while positive for rPFS, showed only a non-significant trend in overall survival (HR 0.77, p=0.09), raising doubts about durable clinical benefit. Similarly, the obesity portfolio depends on Metsera's ultra-long-acting peptides achieving competitive efficacy and tolerability by 2028, yet no Phase III data were discussed in the call, and the first approval target remains two years away. The market may be ignoring the cumulative probability of multiple pipeline failures, especially given that Pfizer's adjusted R&D expenses increased 11% operationally in Q1 2026, reflecting increased spending without proportional near-term output, and the company's history of pipeline attrition suggests that even a 50% success rate across key programs may not generate sufficient revenue to offset the $14–15 billion LOE burden from products like Eliquis, Ibrance, and Xtandi looming through 2030.
The company's cash flow outlook and capital allocation strategy are overly dependent on uncertain legal and regulatory outcomes, creating vulnerability if key assumptions fail to materialize. Pfizer's reaffirmed 2026 guidance and long-term growth narrative hinge heavily on the Vyndamax patent settlement extending exclusivity to mid-2031 and the Belgian Comirnaty court ruling being successfully implemented in Poland and Romania to secure €1.9 billion in vaccine sales. However, the transcript revealed that the Belgian judgment requires execution with local governments, and Alexandre de Germay noted they are "discussing the best path forward to implement that judgment," indicating implementation risk and potential delays or reduced recoveries. Furthermore, the $7 billion BD capacity cited by David Denton includes the $1.65 billion net proceeds from the ViiV stake sale, which closes in Q2 2026—meaning the capacity is not fully available today and depends on timely execution of that transaction. If the ViiV proceeds are delayed or tax liabilities exceed expectations, or if the Comirnaty implementation yields less than anticipated due to political or logistical hurdles in Eastern Europe, Pfizer's deleveraging plan could falter, leaving leverage elevated around 2.8x through 2028 as warned. This overreliance on specific legal wins to enable future share repurchases and dividend growth ignores the execution risk in realizing these benefits, leaving the balance sheet more exposed than management admits during the Q&A.
Pfizer's obesity franchise, while touted as a future growth engine, faces substantial commercial and competitive hurdles that could delay or diminish its impact, particularly in key international markets where the company claims advantage. Although Aamir Malik highlighted Pfizer's ability to activate consumers and its field force touching nearly 60% of physicians likely to write obesity prescriptions, the reality is that the obesity market is becoming fiercely competitive, with Lilly and Novo Nordisk dominating share and investing heavily in disease awareness and access programs. In China, where Pfizer launched ecnoglutide via a partnership with Hangzhou Sciwind Biosciences, the company acknowledged it is "very early day" and could not discuss penetration, yet the partnership structure—Sciwind remains the Marketing Authorization Holder and is eligible for up to $495 million in milestones—suggests Pfizer has limited control over commercialization speed and execution. The upfront nature of the deal, with Pfizer obtaining exclusive commercialization rights but Sciwind handling R&D, manufacturing, and supply, creates dependency on a smaller partner's capabilities in a complex market. Furthermore, while Pfizer sees opportunity in emerging markets like Brazil and Mexico, these regions often have volatile pricing environments, limited formulary access, and complex tender systems that could delay uptake despite high obesity prevalence. The market may be underestimating how difficult it is to gain share in a category where incumbents have entrenched physician relationships, superior delivery devices, and established reimbursement pathways, especially if Pfizer's molecules fail to demonstrate clear differentiation beyond weight loss efficacy in real-world studies.
The company's vaccine franchise, despite recent innovations, faces growing competitive pressures and evolving public health dynamics that could undermine long-term leadership, particularly in the adult pneumococcal market where Pfizer is advancing its 35-valent candidate. While the 25vPnC pediatric data showed strong immunogenicity, the market is not solely driven by scientific superiority; Prevnar 20 already faces increasing competition from rivals like Merck's Vaxneuvance, and the adult vaccine landscape is shifting toward broader serotype coverage driven by emerging strains and changing epidemiology. Pfizer's decision to leap to a 35-valent adult candidate assumes that regulatory pathways will remain favorable and that the proprietary next-generation serotype 3 technology will deliver meaningful clinical differentiation, yet there is no guarantee that health authorities will prioritize valency over cost-effectiveness, especially in publicly funded programs. Furthermore, the adult market introduces complexity: unlike pediatric vaccines tied to routine immunization schedules, adult pneumococcal vaccination relies on risk-based recommendations (e.g., age 50+, immunocompromised) that have lower adherence rates and are more susceptible to shifting guidelines. If CDC or ACIP updates reduce the recommended population or if reimbursement pressures favor lower-valent, cheaper alternatives, Pfizer's investment in a 35-valent candidate could face slower adoption than anticipated. The market may be ignoring how vaccine leadership requires not just scientific innovation but also sustained engagement with public health agencies and payers—a challenge Pfizer has not consistently demonstrated in recent years outside of pandemic-era COVID response.

Pfizer's reliance on its pipeline to offset looming patent expirations faces significant execution risk, particularly in oncology and obesity, where clinical success is far from guaranteed despite management's optimistic framing. The company is targeting approximately 20 pivotal study starts in 2026, including high-stakes readouts for programs like atirmociclib (CDK4 inhibitor), SV (integrin B6C), and Mevro (EZH2 inhibitor), yet the earnings call revealed evasiveness when questioned about specific timelines—for instance, Chris Boshoff noted that amylin mono data from the obesity program would not be shared at ADA and would only come in the second half of the year, signaling potential delays. While management cites statistical confidence in a "large number of pipeline assets risk adjusted," the reality is that late-stage oncology programs carry high failure rates; for example, the TALAPRO-3 study of Talzenna plus Xtandi in mCSPC, while positive for rPFS, showed only a non-significant trend in overall survival (HR 0.77, p=0.09), raising doubts about durable clinical benefit. Similarly, the obesity portfolio depends on Metsera's ultra-long-acting peptides achieving competitive efficacy and tolerability by 2028, yet no Phase III data were discussed in the call, and the first approval target remains two years away. The market may be ignoring the cumulative probability of multiple pipeline failures, especially given that Pfizer's adjusted R&D expenses increased 11% operationally in Q1 2026, reflecting increased spending without proportional near-term output, and the company's history of pipeline attrition suggests that even a 50% success rate across key programs may not generate sufficient revenue to offset the $14–15 billion LOE burden from products like Eliquis, Ibrance, and Xtandi looming through 2030.
The company's cash flow outlook and capital allocation strategy are overly dependent on uncertain legal and regulatory outcomes, creating vulnerability if key assumptions fail to materialize. Pfizer's reaffirmed 2026 guidance and long-term growth narrative hinge heavily on the Vyndamax patent settlement extending exclusivity to mid-2031 and the Belgian Comirnaty court ruling being successfully implemented in Poland and Romania to secure €1.9 billion in vaccine sales. However, the transcript revealed that the Belgian judgment requires execution with local governments, and Alexandre de Germay noted they are "discussing the best path forward to implement that judgment," indicating implementation risk and potential delays or reduced recoveries. Furthermore, the $7 billion BD capacity cited by David Denton includes the $1.65 billion net proceeds from the ViiV stake sale, which closes in Q2 2026—meaning the capacity is not fully available today and depends on timely execution of that transaction. If the ViiV proceeds are delayed or tax liabilities exceed expectations, or if the Comirnaty implementation yields less than anticipated due to political or logistical hurdles in Eastern Europe, Pfizer's deleveraging plan could falter, leaving leverage elevated around 2.8x through 2028 as warned. This overreliance on specific legal wins to enable future share repurchases and dividend growth ignores the execution risk in realizing these benefits, leaving the balance sheet more exposed than management admits during the Q&A.
Pfizer's obesity franchise, while touted as a future growth engine, faces substantial commercial and competitive hurdles that could delay or diminish its impact, particularly in key international markets where the company claims advantage. Although Aamir Malik highlighted Pfizer's ability to activate consumers and its field force touching nearly 60% of physicians likely to write obesity prescriptions, the reality is that the obesity market is becoming fiercely competitive, with Lilly and Novo Nordisk dominating share and investing heavily in disease awareness and access programs. In China, where Pfizer launched ecnoglutide via a partnership with Hangzhou Sciwind Biosciences, the company acknowledged it is "very early day" and could not discuss penetration, yet the partnership structure—Sciwind remains the Marketing Authorization Holder and is eligible for up to $495 million in milestones—suggests Pfizer has limited control over commercialization speed and execution. The upfront nature of the deal, with Pfizer obtaining exclusive commercialization rights but Sciwind handling R&D, manufacturing, and supply, creates dependency on a smaller partner's capabilities in a complex market. Furthermore, while Pfizer sees opportunity in emerging markets like Brazil and Mexico, these regions often have volatile pricing environments, limited formulary access, and complex tender systems that could delay uptake despite high obesity prevalence. The market may be underestimating how difficult it is to gain share in a category where incumbents have entrenched physician relationships, superior delivery devices, and established reimbursement pathways, especially if Pfizer's molecules fail to demonstrate clear differentiation beyond weight loss efficacy in real-world studies.
The company's vaccine franchise, despite recent innovations, faces growing competitive pressures and evolving public health dynamics that could undermine long-term leadership, particularly in the adult pneumococcal market where Pfizer is advancing its 35-valent candidate. While the 25vPnC pediatric data showed strong immunogenicity, the market is not solely driven by scientific superiority; Prevnar 20 already faces increasing competition from rivals like Merck's Vaxneuvance, and the adult vaccine landscape is shifting toward broader serotype coverage driven by emerging strains and changing epidemiology. Pfizer's decision to leap to a 35-valent adult candidate assumes that regulatory pathways will remain favorable and that the proprietary next-generation serotype 3 technology will deliver meaningful clinical differentiation, yet there is no guarantee that health authorities will prioritize valency over cost-effectiveness, especially in publicly funded programs. Furthermore, the adult market introduces complexity: unlike pediatric vaccines tied to routine immunization schedules, adult pneumococcal vaccination relies on risk-based recommendations (e.g., age 50+, immunocompromised) that have lower adherence rates and are more susceptible to shifting guidelines. If CDC or ACIP updates reduce the recommended population or if reimbursement pressures favor lower-valent, cheaper alternatives, Pfizer's investment in a 35-valent candidate could face slower adoption than anticipated. The market may be ignoring how vaccine leadership requires not just scientific innovation but also sustained engagement with public health agencies and payers—a challenge Pfizer has not consistently demonstrated in recent years outside of pandemic-era COVID response.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Drug Manufacturers - General

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LLY	ELI LILLY & Co	1,066.16 Bn	42.18	14.76	43.37 Bn
2	JNJ	Johnson & Johnson	611.69 Bn	29.07	6.35	54.99 Bn
3	ABBV	AbbVie Inc.	444.34 Bn	122.04	7.07	64.53 Bn
4	AZN	Astrazeneca Plc	284.94 Bn	23.78	2,793.52	-24.45 Bn
5	MRK	Merck & Co., Inc.	224.23 Bn	25.00	3.41	49.12 Bn
6	AMGN	Amgen Inc	195.12 Bn	25.02	5.24	57.32 Bn
7	GILD	Gilead Sciences, Inc.	156.45 Bn	16.36	5.26	22.17 Bn
8	PFE	Pfizer Inc	136.01 Bn	11,334.57	5.56	64.46 Bn

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password